openPR Logo
Press release

Dengue Fever Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight |Kino Pharma, Abivax, Plex Pharma, Codagenix, Atea Pharma

04-05-2024 03:20 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Dengue Fever Pipeline and Clinical Trials Assessment, 2024

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Dengue Fever pipeline constitutes 10+ key companies continuously working towards developing 10+ Dengue Fever treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Dengue Fever Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Dengue Fever Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dengue Fever Market.

Some of the key takeaways from the Dengue Fever Pipeline Report:

* Companies across the globe are diligently working toward developing novel Dengue Fever treatment therapies with a considerable amount of success over the years.
* Dengue Fever companies working in the treatment market are Kino Pharma, Abivax, Plex Pharmaceuticals, Codagenix, Atea Pharmaceuticals, Emergex Vaccines, Visterra, Janssen Research & Development, Merck & Co., Takeda, and others, are developing therapies for the Dengue Fever treatment

* Emerging Dengue Fever therapies such as - anti-RNA virus therapeutics, ABX220, Infectious diseases therapeutics Programme, CDX DENV, AT-752, LD vehicle-GNP, VIS513, JNJ-64281802, TV003, V 503, and others are expected to have a significant impact on the Dengue Fever market in the coming years.
* In Febuary 2024, The TAK-003 vaccine represents a novel approach to combatting dengue fever in regions heavily impacted by the disease.

Dengue Fever Overview

Dengue fever is a viral infection transmitted primarily by the Aedes mosquito, particularly Aedes aegypti. It is caused by the dengue virus, which belongs to the Flaviviridae family. Dengue fever is prevalent in tropical and subtropical regions, including Southeast Asia, the Pacific Islands, the Caribbean, and parts of Central and South America.

Get a Free Sample PDF Report to know more about Dengue Fever Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/dengue-fever-pipeline-insight [https://www.delveinsight.com/report-store/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Dengue Fever Drugs Under Different Phases of Clinical Development Include:

* Research programme: anti-RNA virus therapeutics - Kino Pharma
* ABX220: Abivax
* Infectious diseases therapeutics Programme: Plex Pharmaceuticals
* CDX DENV: Codagenix
* AT-752: Atea Pharmaceuticals
* LD vehicle-GNP: Emergex Vaccines
* VIS513: Visterra
* JNJ-64281802: Janssen Research & Development
* TV003: Merck & Co.
* V 503: Takeda

Route of Administration

Dengue Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

* Subcutaneous
* Intravenous
* Intramuscular
* Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

* Small molecules
* Proteins
* Monoclonal antibodies
* Product Type

Dengue Fever Pipeline Therapeutics Assessment

* Dengue Fever Assessment by Product Type
* Dengue Fever By Stage and Product Type
* Dengue Fever Assessment by Route of Administration
* Dengue Fever By Stage and Route of Administration
* Dengue Fever Assessment by Molecule Type
* Dengue Fever by Stage and Molecule Type

DelveInsight's Dengue Fever Report covers around 10+ products under different phases of clinical development like

* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration

Further Dengue Fever product details are provided in the report. Download the Dengue Fever pipeline report to learn more about the emerging Dengue Fever therapies [https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Dengue Fever Therapeutics Market include:

Key companies developing therapies for Dengue Fever are - Takeda Pharmaceutical Co Ltd, BioNet-Asia Co Ltd, Emergex Vaccines Holding Ltd, Johnson & Johnson, 60 Degrees Pharmaceuticals LLC, and Abivax SA among others.

Dengue Fever Pipeline Analysis:

The Dengue Fever pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Dengue Fever with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dengue Fever Treatment.
* Dengue Fever key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Dengue Fever Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dengue Fever market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Dengue Fever drugs and therapies [https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dengue Fever Pipeline Market Drivers

* Fastest spreading mosquito-borne viral disease, search of novel tools and innovative strategies to interrupt transmission of dengue, integration of vector management approaches is encouraged are some of the important factors that are fueling the Dengue Fever Market.

Dengue Fever Pipeline Market Barriers

* However, challenging research due to multiple stereotypes, disease risks may change and shift with climate change in tropical and subtropical areas and other factors are creating obstacles in the Dengue Fever Market growth.

Scope of Dengue Fever Pipeline Drug Insight

* Coverage: Global
* Key Dengue Fever Companies: Kino Pharma, Abivax, Plex Pharmaceuticals, Codagenix, Atea Pharmaceuticals, Emergex Vaccines, Visterra, Janssen Research & Development, Merck & Co., Takeda, and others
* Key Dengue Fever Therapies: anti-RNA virus therapeutics, ABX220, Infectious diseases therapeutics Programme, CDX DENV, AT-752, LD vehicle-GNP, VIS513, JNJ-64281802, TV003, V 503, and others
* Dengue Fever Therapeutic Assessment: Dengue Fever current marketed and Dengue Fever emerging therapies
* Dengue Fever Market Dynamics: Dengue Fever market drivers and Dengue Fever market barriers

Request for Sample PDF Report for Dengue Fever Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1

Dengue Fever Report Introduction

2

Dengue Fever Executive Summary

3

Dengue Fever Overview

4

Dengue Fever- Analytical Perspective In-depth Commercial Assessment

5

Dengue Fever Pipeline Therapeutics

6

Dengue Fever Late Stage Products (Phase II/III)

7

Dengue Fever Mid Stage Products (Phase II)

8

Dengue Fever Early Stage Products (Phase I)

9

Dengue Fever Preclinical Stage Products

10

Dengue Fever Therapeutics Assessment

11

Dengue Fever Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Dengue Fever Key Companies

14

Dengue Fever Key Products

15

Dengue Fever Unmet Needs

16

Dengue Fever Market Drivers and Barriers

17

Dengue Fever Future Perspectives and Conclusion

18

Dengue Fever Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dengue-fever-pipeline-and-clinical-trials-assessment-2024-updates-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-kino-pharma-abivax-plex-pharma-codagenix-atea-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dengue Fever Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight |Kino Pharma, Abivax, Plex Pharma, Codagenix, Atea Pharma here

News-ID: 3453920 • Views:

More Releases from ABNewswire

Understanding Magnetic Switches: Types, Working Principles, and Applications
Understanding Magnetic Switches: Types, Working Principles, and Applications
A magnetic switch is a versatile electrical device that operates by responding to magnetic fields. From Hall Effect to reed switches, explore their functions, types, and diverse applications. What is a Magnetic Switch? A magnetic switch is an electrical device that operates by responding to the presence of a magnetic field. It functions by closing or opening its contacts based on the strength of the magnetic field. Specifically, the switch remains closed
Innovating embedded downlight technology: Leading the global trend of intelligent, efficient and customized lighting
Innovating embedded downlight technology: Leading the global trend of intelligen …
The strong rise of China's manufacturing industry has profoundly reshaped the technological landscape and development trajectory of embedded downlights. With its unparalleled industrial chain advantages, continuous technological innovation, and significant cost-effectiveness, Chinese enterprises have risen from participants in the global lighting industry to undisputed leaders. This transformation goes far beyond the huge production scale; it lies in the thorough innovation of the core technical content and application boundaries of embedded
North China Electric Power University Foreign Aid Training Program Visits Yiyuan Tech for Exchange
North China Electric Power University Foreign Aid Training Program Visits Yiyuan …
On July 23, 2025, the Electrical Industry Training Program of North China Electric Power University's Foreign Aid Project visited Yiyuan Technology for an exchange visit. The purpose was to gain in-depth insights into the company's innovations in renewable energy technology promotion and application [https://www.yiyen.com/about/], and to build bridges connecting university-enterprise cooperation with foreign aid initiatives. Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-1.jpg Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-3.jpg Upon arrival, the delegation received a warm welcome from company leadership and the reception
Pure Sine Wave Low Frequency Inverter Charger
Pure Sine Wave Low Frequency Inverter Charger
Pure sine wave low frequency inverter [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] is widely used and suitable for a variety of scenarios. In terms of home backup power, it can provide reliable power during power outages, ensuring that essential appliances such as refrigerators, air conditioners and medical equipment continue to operate . For solar power generation systems, Inverter charger [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] can converter DC Power from Battery, which charged by solar panels, into clean alternating current

All 5 Releases


More Releases for Dengue

Key Trend Reshaping the Dengue Treatment Market in 2025: Innovative Drug Deliver …
Which drivers are expected to have the greatest impact on the over the dengue treatment market's growth? The escalation in cases of dengue is projected to stimulate the expansion of the market for dengue treatments. Dengue is a viral infection transmitted by mosquito bites, causing symptoms akin to the flu and can escalate to intense complications if not treated. The escalation is primarily due to progressing urbanization, climate alterations favourable to
Key Dengue Vaccine Market Trend for 2025-2034: Advancements In Dengue Tetravalen …
What Is the Future Outlook for the Dengue Vaccine Market's Size and Growth Rate? In the past few years, the dengue vaccine market has experienced significant growth. From $0.64 billion in 2024, it is projected to reach $0.72 billion in 2025, marking a compound annual growth rate (CAGR) of 12.4%. This notable expansion during the historical period can be credited to factors such as an increase in travel and urbanization trends,
Dengue Vaccine Market : An Detailed Overview
Introduction: Dengue fever is a mosquito-borne viral infection caused by the dengue virus, transmitted primarily through Aedes aegypti and Aedes albopictus mosquitoes. Affecting millions globally each year, dengue has become a significant public health concern, especially in tropical and subtropical regions. The development of dengue vaccines represents a groundbreaking advancement in preventing the disease, reducing its associated healthcare costs, and controlling outbreaks. With increasing awareness and investments in immunization programs, the
Dengue Vaccine Market : An Overview
Introduction: Dengue fever is a mosquito-borne viral infection that has become a significant public health challenge in tropical and subtropical regions. The disease is caused by the dengue virus, which is transmitted primarily by Aedes aegypti mosquitoes. With approximately 390 million infections annually, dengue fever places a substantial burden on healthcare systems and economies worldwide. Efforts to mitigate this burden have led to the development of dengue vaccines, designed to prevent
"Rising Incidence of Dengue Fever Propels Dengue Virus Diagnostic Tests Market T …
According to WHO, dengue affects about 50-100 million people worldwide, annually. It is a vector-borne highly communicable disease. This report discusses the diagnostic tests used to confirm the presence of dengue in one individual. It is true that the growth of the global dengue virus diagnostic tests market is primarily driven by an increase in the incidence of dengue fever, which is a mosquito-borne viral infection that can cause severe flu-like
Dengue Vaccines Market 2021 | Detailed Report
Dengue Vaccines Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027. Get Free Sample PDF (including full TOC, Tables and Figures) of Dengue Vaccines Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=4644240 The report provides a comprehensive analysis of company profiles listed below: - Sanofi - Takeda Dengue Vaccines Market Segment by